文献速递肝病胰腺与胆道疾病

IgG4相关胆管炎——纤维化性和恶性胆管病的模仿者

IgG4-related cholangitis - a mimicker of fibrosing and malignant cholangiopathies.
PubMed 文献 · J Hepatol · 2023-08-18

本文综述IgG4相关胆管炎(IRC)的发病机制、临床表型、诊断与治疗。IRC常模仿原发性硬化性胆管炎或胆管癌,可导致不恰当的医疗甚至致残性手术干预;因缺乏特异性生物标志物,诊断依据HISORt标准。糖皮质激素对诱导缓解高度有效,免疫调节剂可作为减少激素用量的维持缓解替代方案。

要点

  • IRC是IgG4相关疾病的主要肝胆表现,临床常模仿原发性硬化性胆管炎或胆管癌。
  • 诊断依据HISORt标准,涵盖组织病理学、影像学、血清学、其他器官表现及治疗反应。
  • 治疗包括诱导缓解、维持缓解和长期管理;糖皮质激素诱导缓解高度有效。

核心结论

  • IRC是IgG4相关疾病的主要肝胆表现,临床常模仿其他胆道疾病如原发性硬化性胆管炎或胆管癌,可能导致不恰当的医疗和潜在致残性手术干预。
  • 糖皮质激素对诱导缓解高度有效,之后可引入免疫调节剂作为减少糖皮质激素用量的维持缓解替代方案。
  • 随着对IRC发病机制认识的深入,未来将带来诊断的改善和新的治疗策略。

研究设计与样本

  • 综述,总结IgG4相关胆管炎的发病机制、临床表型、诊断标准与治疗策略。

主要发现

  • IgG4相关疾病和IRC的发病机制目前被认为是多因素的,存在遗传易感性证据,而环境因素如蓝领工作为主要危险因素。
  • IgG4相关疾病中已描述多种自身抗原,包括annexin A11和laminin 511-E8,后者可能分别通过增强分泌和屏障功能在胆管细胞中发挥部分保护作用。
  • IRC患者中存在IgG4+浆母细胞的寡克隆扩增,成功治疗后消失。
  • 调节性T细胞、滤泡性T辅助2细胞、外周T辅助细胞及细胞毒性CD8+和CD4+ SLAMF7+ T细胞等特定T细胞亚型与IgG4相关疾病发病机制相关。

关键数值与推荐

  • IRC诊断依据HISORt标准,包括组织病理学、影像学、血清学、其他器官表现和对治疗的反应。
  • 治疗包括(i)诱导缓解、(ii)维持缓解和(iii)长期管理。
  • 糖皮质激素对诱导缓解高度有效,之后可引入免疫调节剂作为减少糖皮质激素用量的维持缓解替代方案。

临床怎么用

  • IRC临床常模仿原发性硬化性胆管炎或胆管癌,可能导致不恰当的医疗和潜在致残性手术干预。
  • 因缺乏特异性生物标志物,诊断依据HISORt标准。
  • 治疗目标为预防或减轻器官损伤并改善症状,包括诱导缓解、维持缓解和长期管理。
  • 糖皮质激素对诱导缓解高度有效,免疫调节剂可作为减少糖皮质激素用量的维持缓解替代方案。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IgG4-related cholangitis (IRC) is the major hepatobiliary manifestation of IgG4-related disease (IgG4-RD), a systemic fibroinflammatory disorder. The pathogenesis of IgG4-RD and IRC is currently viewed as multifactorial, as there is evidence of a genetic predisposition while environmental factors, such as blue-collar work, are major risk factors. Various autoantigens have been described in IgG4-RD, including annexin A11 and laminin 511-E8, proteins which may exert a partially protective function in cholangiocytes by enhancing secretion and barrier function, respectively. For the other recently described autoantigens, galectin-3 and prohibitin 1, a distinct role in cholangiocytes appears less apparent. In relation to these autoantigens, oligoclonal expansions of IgG4+ plasmablasts are present in patients with IRC and disappear upon successful treatment. More recently, specific T-cell subtypes including regulatory T cells, follicular T helper 2 cells, peripheral T helper cells and cytotoxic CD8+ and CD4+ SLAMF7+ T cells have been implicated in the pathogenesis of IgG4-RD. The clinical presentation of IRC often mimics other biliary diseases such as primary sclerosing cholangitis or cholangiocarcinoma, which may lead to inappropriate medical and potentially invalidating surgical interventions. As specific biomarkers are lacking, diagnosis is made according to the HISORt criteria comprising histopathology, imaging, serology, other organ manifestations and response to therapy. Treatment of IRC aims to prevent or alleviate organ damage and to improve symptoms and consists of (i) remission induction, (ii) remission maintenance and (iii) long-term management. Glucocorticosteroids are highly effective for remission induction, after which immunomodulators can be introduced for maintenance of remission as glucocorticosteroid-sparing alternatives. Increased insight into the pathogenesis of IRC will lead to improved diagnosis and novel therapeutic strategies in the future.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Kersten R, Trampert DC, Herta T, et al. IgG4-related cholangitis - a mimicker of fibrosing and malignant cholangiopathies. J Hepatol. 2023. PMID: 37598939. doi:10.1016/j.jhep.2023.08.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。